Besqab trades at 4-6x 2027-28E adj. EPS. We argue valuation is low and believe there is potential fo...
Redeye shares its preview of Physitrack’s Q3 2026 results ahead of the report on 20 October.
* Q3e EBITA +11% y-o-y to SEK 88m * We raise '27e EBITA 2% on Svedbergs savings * We reiterate our f...
Redeye retains its forecasts and Base Case of SEK8.
Seafire’s earnings momentum is set to moderate temporarily in Q3/26E, reflecting challenging compara...
We expect a more supportive trading backdrop in Q3, helped by a favourable seasonal mix, encouraging...
Avensia launches a SEK13m cost-saving programme in Commerce.
Redeye comments on Faron’s announcement that the first patient has been dosed in the investigator-in...
Redeye comments on Gentoo Media's updated guidance following softer than expected development in Q3 ...
Kalqyl publicerar nu en sektorrapport om tio svenska mjukvarubolag med olika nischinriktningar och a...
Q2 output growth accelerated. Total output rose 31% yoy to € 10.
We leave our Base Case unchanged at SEK44 ahead of the Q3 report on 22 October, as the quarter shoul...
Redeye views today's news positively, as AAC Clyde Space’s largest shareholder, Bonnier Capital, has...
Redeye comments on this morning's press release, in which Cantargia reports preclinical data on nadu...
Redeye comments on Alzinova's announcement that it has completed its research collaboration with Ams...
Vuxen inledde 2026/27 med en omsättningstillväxt på 27,0 % till 66,3 MSEK (52,2), bolagets högsta om...
Bittium announced today that it will renew its organisational structure, merging Defence & Security ...
Redeye briefly comments on yesterday’s announcement that OncoZenge has resolved on two directed shar...
Following a change of analyst, we make minor changes to our medium-term growth assumptions while kee...
* Sequential sales decline, but order activity has improved * We cut '26e-'28e EBIT by 11-8% on lowe...